Pro-Pharmaceuticals Private Placement (OTC:PRWP)
Source: http://feedproxy.google.com/~r/FavStocks/~3/bRTrdxJ3fgw/Posted on Thursday, November 5th, 2009 | In Biotech, Investing Lessons, Stocks to Watch
Pro-Pharmaceuticals, Inc. (OTC:PRWP) has announced that they have closed a US$310,000 tranche of a private placement for up to US$6.0 million with 10X Fund, L.P. which is purchasing their unregistered Series B convertible preferred stocks and warrants. This tranche brings the total raised to date from the 10X Fund to approximately US$4.1 million. Pro-Pharmaceuticals is one of the leading companies that is engaged in the discovery, development and commercialization of carbohydrate therapeutics for the advanced treatment of patients suffering from cancer and fibrosis. Other products that are in the pipeline focus more on decreasing the toxicity of chemotherapy drugs.
The Company has decided to use the proceeds from the financing of partnership development and approval in countries with their own approval process as well as for general corporate purposes. At the closing of the tranche, the Company issued and sold 155,000 shares of Series B-2 preferred stock convertible into 620,000 shares of common stock, a Class A-1 and Class A-2 warrant each exercisable to purchase 310,000 shares of common stock and Class B warrant exercisable to purchase 1,240,000 shares of common stock for a gross purchase price of US$310,000 and the net proceeds were US$296,000 approximately. The Company also announced that Series B Preferred Stock, Class A-1 and A-2 warrants and Class B warrants are not registered and therefore cannot be sold or offered.
Currently, DAVANAT is the leading product candidate of Pro-Pharmaceuticals Inc, which is a carbohydrate polymer that targets galectin receptors that are over-expressed on the cancer cell. As per the research galectin affects the development of cell and plays important role in cancer, including tumor cell survival, angiogenesis and tumor metastasis. So far DAVANAT has been administered on 100 patients suffering from cancer and the data from Phase 2 trial showed that it is effective in reducing the side effects of the chemotherapy.
Last 5 posts by Jay Garcilazo
- Dyax approaching its PDUFA Date (DYAX) - November 24th, 2009
- FDA Decision scheduled for Santarus (SNTS) - November 23rd, 2009
- FDA Decision scheduled for Santarus (SNTS) - November 23rd, 2009
- CytRx Technical Breakout on Pending News (NASDAQ:CYTR) - November 23rd, 2009
- CytRx Technical Breakout on Pending News (NASDAQ:CYTR) - November 23rd, 2009
 About Jay Garcilazo (http://favstocks.com)
I grew up in Boca Raton, Florida. After graduating high school I enrolled at Florida State University where I studied Journalism and Political Science. It was around this time that I got a job in the healthcare industry, a job that would give me a lot of experience as I worked and moved up over the next four and a half years. This along with working for a hedge fund manager for years, were the greatest learning experiences of my life so far. I have also been fortunate enough to have lived all over the country in, Austin, Texas, Queens, New York, Great Falls, Montana, Cleveland, Ohio, Chattanooga, Tennessee, Atlanta, Georgia, and all over the state of Florida. As well as living in many places I have traveled all over, been to all of the states except California (Had a layover at LAX once but I don’t think that counts), Oregon, and Hawaii. Traveled most of the Caribbean, I have also been to many destinations in Canada, and Mexico. I even did a stint through Europe. As well as traveling and living all over I have also worked in a great many industries. I have been employed in finance, healthcare, title, mortgage, travel, video game development, hospitality, and news industries. Besides working for an investment company I have also done quite a bit of investing on my own, and through trial and error, learning from mistakes, and watching the news very closely I have made some decent money for myself. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.